Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Switzerland’s president and other top officials are traveling to Washington in a hastily arranged trip aimed at striking a ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Today, the regulator revealed FDA PreCheck, which introduces a two-phase approach to getting approval for new production ...

On July 15, 2025, Judge Evelyn Padin of the District of New Jersey denied Novartis’s motion for preliminary injunction, which ...

Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. in a bid to boost its drug ...

Genmab (NASDAQ: GMAB) also cited higher sales of its own cancer drug EPKINLY as a key driver of its performance. Meanwhile, net sales of DARZALEX rose 22% to $6.78 billion over the period.